Manufacturability and functionality assessment of different formats of T-cell engaging bispecific antibodies

被引:6
|
作者
Loh, Han Ping [1 ]
Mahfut, Farouq Bin [1 ]
Chen, Serene W. [1 ]
Huang, Yuhan [2 ]
Huo, Jianxin [2 ]
Zhang, Wei [1 ]
Lam, Kong Peng [2 ,5 ]
Xu, Shengli [2 ,3 ,5 ]
Yang, Yuansheng [1 ,4 ]
机构
[1] ASTAR, Bioproc Technol Inst BTI, Singapore, Singapore
[2] ASTAR, Singapore Immunol Network SIGN, Singapore, Singapore
[3] Natl Univ Singapore, Yong Loo Lin Sch Med, Physiol, Singapore, Singapore
[4] ASTAR, Bioproc Technol Inst BTI, 20 Biopolis Way,06-01 Ctr, Singapore 138668, Singapore
[5] ASTAR, Singapore Immunol Network SIGN, 8A Biomed Grove,04-06 Immunos, Singapore 138468, Singapore
关键词
CHO cell; avidity; bispecific antibody; functionality; manufacturability; targeted integration; thermal stability; STRUCTURE-BASED DESIGN; VARIABLE DOMAINS; IGG ANTIBODIES; IMMUNOGLOBULIN; STABILITY; GENERATION; SCFV;
D O I
10.1080/19420862.2023.2231129
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
T-cell-engaging bispecific antibodies (T-bsAbs) are promising immunotherapies for cancer treatment due to their capability of redirecting T-cells toward destroying tumor cells. Numerous T-bsAb formats have been developed, each with advantages and disadvantages in terms of developability, immunogenicity, effector functions, and pharmacokinetics. Here, we systematically compared T-bsAbs produced using eight different formats, evaluating the effect of molecular design of T-bsAbs on their manufacturability and functionality. These eight T-bsAb formats were constructed using antigen-binding fragments (Fabs) and single-chain variable fragments (scFvs) of antibodies linked to the crystallizable fragment (Fc) domain of immunoglobulin G. To ensure a fair comparison of growth and production data, we used recombinase-mediated cassette exchange technology to generate the T-bsAb-producing CHO cell lines. The produced T-bsAbs were assessed for their purification profile and recovery, binding capability, and biological activities. Our findings indicated that the manufacturability of bsAbs was adversely affected with increased number of scFv building blocks, while the functionality was affected by the combination of multiple factors, including the binding affinity and avidity of targeting moieties and the flexibility and geometry of formats. These results provide valuable insights into the impact of the format design on the optimal production and function of T-bsAbs.
引用
收藏
页数:17
相关论文
共 50 条
  • [1] Bispecific T-Cell Engaging Antibodies for Cancer Therapy
    Baeuerle, Patrick A.
    Reinhardt, Carsten
    CANCER RESEARCH, 2009, 69 (12) : 4941 - 4944
  • [2] Masking T-Cell Engaging Bispecific Antibodies for Safer Cancer Immunotherapy
    McCue, Amelia
    Froning, Karen
    Antonysamy, Stephen
    Demarest, Stephen
    Kuhlman, Brian
    PROTEIN SCIENCE, 2023, 32 (12)
  • [3] First-in-Human Dose Selection for T-Cell Engaging Bispecific Antibodies
    van Der Graaf, Piet H.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2025, 117 (01) : 11 - 13
  • [4] Novel tetravalent bispecific T-cell engaging antibodies for cancer immunotherapy.
    Lakshmikanthan, Sribalaji
    Wyant, Timothy
    Pandian, Swarna
    Murphy, Shaun
    Chen, Yangde
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [5] Translation and Clinical Development of Bispecific T-cell Engaging Antibodies for Cancer Treatment
    Yuraszeck, T.
    Kasichayanula, S.
    Benjamin, J. E.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2017, 101 (05) : 634 - 645
  • [6] T-cell-engaging bispecific antibodies in cancer
    Donk, Niels W. C. J. van de
    Zweegman, Sonja
    LANCET, 2023, 402 (10396): : 142 - 158
  • [7] Nephrotoxicity in Bispecific Antibodies Recipients: Focus on T-Cell-Engaging Bispecific Antibodies
    Wen, Xiaoli
    Xu, Gaosi
    ONCOTARGETS AND THERAPY, 2024, 17 : 545 - 556
  • [8] Blinatumomab: A novel, bispecific, T-cell engaging antibody
    May, Megan Brafford
    Glode, Ashley
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2016, 73 (01) : E6 - E13
  • [9] The expanding success of T cell-engaging bispecific antibodies
    Bargou, Ralf C.
    NATURE CANCER, 2023, 4 (08) : 1054 - 1055
  • [10] The expanding success of T cell-engaging bispecific antibodies
    Ralf C. Bargou
    Nature Cancer, 2023, 4 : 1054 - 1055